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Ewing’ssarcoma’srelapserarelyoccursmorethantwoyearsaftertheinitialdiagnosis.Wereportthecaseofa26-year-oldmanwith
ahistoryofEwing’ssarcomaoftheleftmaxillarysinusattheageof10whopresentedwithaverylatelocalrelapse,16yearsafterthe
ﬁrst occurrence of disease. Ultimate control was achieved after multimodal therapy including surgery, high-dose chemotherapy,
and radiotherapy. This report indicates that local relapses of Ewing’s sarcoma can be treated with curative intent in selected cases.
Copyright © 2008 J. Thariat et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Ewing’s sarcoma usually occurs before 30 with a peak
incidence at 15 years of age. It represents 5% of all primary
bone tumors and is the second most common malignant
bone tumor in children. It is extremely rare in the head
and neck as it represents 3% of osseous Ewing’s sarcoma
(OES) [1]. The mandible is most frequently aﬀected. Only
six cases of maxillary sinus OES have been reported to date
[2]. Children are usually omitted radiation therapy as long
as complete resection can be achieved to avoid radiation-
induced growth defects and the risk of radiation-induced
sarcomas [3]. Late relapses have seldom been described [4–
6]. We report here an observation corresponding, to the
best of our knowledge, to the longest period of complete
remission followed by local relapse thus far described and
discussed its clinical implications.
Case 1. A 26-year-old man self-referred for isolated mod-
erately paced painless swelling of the left nasal ala with no
physical status deterioration. His past medical history was
remarkable for Ewing’s sarcoma of the left maxillary sinus at
the age of 10 (stage T2N0M0 and IIA with radical margins
according to the American Joint Committee on Cancer
(AJCC) and Musculoskeletal Tumor Society (MSTS) staging
systems, resp.). The patient had been treated according to
the Soci´ et´ eF r a n c ¸aise d’Oncologie P´ ediatrique (SFOP’s) pro-
tocol with chemotherapy, hemimaxillectomy and palatine
prosthetic reconstruction, and postoperative chemotherapy
without radiation therapy because of the absence of residual
viable tumor cells in the tumor resection specimen. The
protocol was adapted from the SFOP guidelines and con-
sisted of (1) initial chemotherapy with cyclophosphamide-
doxorubicin, (2) radical surgery if possible (children were
stratiﬁed for chemotherapy and radiation on histological
response: patients with less than 10% tumor cells on
resection specimen and clear margins (complete resection)
were considered good responders and were omitted local
radiotherapy), and (3) maintenance chemotherapy (for up
to 9 months) with actinomycin-vincristine.
Swelling had worsened over the past three months
and discharge appeared over the past month. Examination
was consistent with a large mucocele of the left nose
area. On computerized tomography (CT) scan, a 19-mL
contrast-enhanced lesion with central sunburst pattern and
calciﬁcations (Figure 1) was noted in the para-nasal and
cheek soft-tissues. It extended medially into the surrounding
nasal bone structures and posteriorly into the left maxillary2 Sarcoma
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Figure 1: CT scan showing a contrast-enhanced lesion with central sunburst pattern and calciﬁcations black asterisk (upper (axial view),
lower (sagittal view)) was noted in the para-nasal and cheek soft-tissues. It extended medially into the surrounding nasal bone structures
and posteriorly into the left maxillary sinus and nasal fossa. It extended superiorly to palatine prosthesis black square. Insert on Figure 1(a)
shows conformational radiotherapy plan (according to Euro-Ewing 99 recommendations). Initial tumor volume was treated with a 2cm
margin and included posttherapeutic scar tissue area white asterisk.
Figure 2: (Histological examination) HES × 600 small-round-
blue-cell arrow head tumor with highly cellular areas. Insert (gross
examination) showed a pseudoencapsulated ﬂeshy tumor mass.
sinus and nasal fossa. Caldwell Luc operation revealed a
ﬂeshy purple lesion. The lesion was easily resectable from
subcutaneous soft tissues but was largely extending into
the frontal process of the surrounding maxillary bone.
Resectionwasthereforesuboptimal(macroscopicallyincom-
plete). Grossly, the lesion appeared as a purple matter with
areas of hemorrhage and necrosis (Figure 2). Histologically,
it was a small-round-blue-cell tumor with homogenous
highly cellular areas spread apart by conjonctival septa
and hemorrhagic lakes. Cells had round hyperchromatic
nuclei and scant cytoplasm. Histology was consistent with
the diagnostic of Ewing’s sarcoma. A molecular cytoge-
netic analysis was performed. R-banded metaphase cells
showed a characteristic t(11;22)(q24;q12) translocation. A
rearrangement of the EWSR1 (22q12) gene was detected
by ﬂuorescence in situ hybridization with a speciﬁc locus
probe. These ﬁndings conﬁrmed the histological diagnosis
of Ewing’s sarcoma. Whole body workup including thoracic
and abdominal CT scan, multiple bone marrow biopsies,
and aspirates showed no additional abnormality (stage
rT1N0M0 at relapse). Chemotherapy consisted of four
cycles of doxorubicin ifosfamide followed by intensiﬁcation
withhigh-dosebusulfan-cyclophosphamidewithautologous
peripheral-blood stem cell rescue. Complete response to
chemotherapy was achieved. Conformational radiation ther-
apy (54Gy) was prescribed according to Euro Ewing 99
protocol [7] due to both suboptimal resection at relapse and
recurrent disease in the adulthood. The patient is alive and
well with no evidence of disease 15 months after diagnosis of
relapse.
2. DISCUSSION
Multimodality therapy for Ewing’s sarcoma is associated
with markedly improved survival rates. Surgery followed
by adjuvant radiotherapy and multiagent chemotherapy has
dramatically improved ﬁve years survival rates to 70%,
compared with single—or even dual—modality therapy
[8]. In our case, the patient had not been treated with
radiotherapy at initial diagnosis because of the absence of
residual disease following surgical resection. The choice of
local control treatment modalities depends on several factors
including tumor site, tumor size, and age [9]. Survival rates
in patients with Ewing’s sarcoma of the head and neck
may be better than those of patients with tumors in other
locations but vary depending on the bone involved [10]J .T h a r i a te ta l . 3
and the possibility to perform surgery. Complete surgical
excision is undertaken whenever possible as nonsurgical
treatment is associated with a poorer long-term survival
rate than that of a treatment regimen that includes surgery.
Radiotherapy has been used historically for the treatment of
Ewing’s sarcomas, as those sarcomas are relatively radiosen-
sitive [11]. However, a signiﬁcant proportion of children
treated with radiotherapy develop late toxicity, including
growth defects and occurrence of second malignancies [3].
Therefore, radiotherapy is not recommended for children
in whom surgical resection can be performed with clear
margins. However, most treatment failures in patients who
do not have distant metastases at presentation result from
local recurrence. Moreover, adjuvant radiotherapy has been
associatedwithimprovedlocalcontrolandimprovessurvival
when compared to surgery or radiotherapy alone [9, 12].
Finally, it might be questioned whether radiotherapy should
have been advocated initially in our patient. As there was
no evidence for any microscopic disease after dose-intense
chemotherapy and complete surgery, it was estimated that
the beneﬁt of increased local control in this case would have
exceeded the risk of toxicity.
Early metastatic relapse has the poorest prognosis [13].
Collins’ law states [14] that for mesenchymal tumors of
the childhood, the period of risk for tumor recurrence is
the age of the child at diagnosis plus nine months. On the
other hand, 85% of the relapses occur within three years
[13, 15]. However, some relapses occur later than ﬁve years
after initial diagnosis. Of those, metastatic relapses are by
far the most common [4–6, 16]. One case only of regional
relapse has been described 17 years after diagnosis in one
series[5].Toourknowledge,nosuchlatestrictlylocalrelapse
in the head and neck area as in our case has been reported
so far. Such rare occurrences may be misdiagnosed. Had
our patient not been particularly aware of his past medical
history and given the mucocele-like aspect of his relapse in
the head and neck area, he might have not been treated
adequately in nonspecialized centers. Such late local relapse
might question whether the patient had in fact a late relapse
of his initial tumor or a clonally distinct recurrence. The
most reliable method to answer this question would have
beentoanalyzethe fusiongenesequenceinboth the primary
and relapsed tumor pathologic specimens. Unfortunately,
initial pathologic specimens were not available in our case.
Five-year survival after relapse is less than 10% but
selected patients beneﬁt from aggressive salvage treatment
[13]. In particular, late relapses may be treated with curative
intent as in our case. Indeed, patients with longer time
to ﬁrst recurrence represent the subset of patients most
likely to survive following recurrence [15] provided that
the diagnosis is not delayed to a point, where disease is no
longer manageable with optimal maximum dose-intensity
treatment.
Finally, the patient is well and free of disease 15 months
after relapse. While followup following treatment of relapse
is still short, intensive salvage multimodality treatment
including radiotherapy for local relapse was feasible and
ultimate tumor control was achieved.
3. CONCLUSION
Such past medical history as Ewing’s sarcoma must not be
overlooked when facing apparently benign tumor since very
latelocalrelapseispossible.Ultimatecontrolcanbeachieved
for local relapses of Ewing’s sarcoma in the adulthood
with aggressive salvage treatment protocols. Further data are
needed to assess the role of aggressive local treatment.
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